ALB Stock Analysis: Albemarle | NYSE
Specialty Chemicals | NYSE, USA | Market Cap: 15.835m USD | 12M Return: 83.9% | US0126531013 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 270M
Qual. Beats: 0
Rev. Trend: -82.8%
Qual. Beats: 3
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Albemarle Corporation (NYSE: ALB) is a U.S.-based specialty chemicals producer headquartered in Charlotte, North Carolina, operating through three segments: Energy Storage, Specialties, and Ketjen. The Energy Storage segment supplies lithium compounds such as lithium carbonate, lithium hydroxide, and lithium chloride used primarily in batteries for electric vehicles, consumer electronics, and grid and solar energy storage. The Specialties segment produces bromine-based chemicals, specialty lithium products (including butyllithium and lithium aluminum hydride), cesium, zirconium, barium, and titanium compounds for industries including fire safety, pharmaceuticals, and pyrotechnics. The Ketjen segment provides hydroprocessing, fluidized catalytic cracking, and alkylation catalysts used in petroleum refining, along with organometallic and curative catalyst solutions.
Albemarle serves a diverse end-market base spanning grid storage, automotive, aerospace, conventional energy, electronics, construction, agriculture, food, and pharmaceuticals. The company is classified within the Materials sector under the Specialty Chemicals sub-industry, and as one of the worlds largest integrated lithium producers, its earnings are closely tied to lithium pricing cycles and EV battery demand growth. Founded in 1887, Albemarle has a long operational history in industrial and fine chemicals.
- Lithium prices slide on weakening EV demand
- Energy Storage margins compress amid oversupply
- Specialties bromine business delivers stable cash flow
| Net Income: 224.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 9.57 > 1.0 |
| NWC/Revenue: 34.75% < 20% (prev 51.18%; Δ -16.43% < -1%) |
| CFO/TA 0.11 > 3% & CFO 1.80b > Net Income 224.2m |
| Net Debt (457.2m) to EBITDA (1.23b): 0.37 < 3 |
| Current Ratio: 2.09 > 1.5 & < 3 |
| Outstanding Shares: last quarter (136.2m) vs 12m ago 15.76% < -2% |
| Gross Margin: 23.89% > 18% (prev 7.72%; Δ 16.17% > 0.5%) |
| Asset Turnover: 35.59% > 50% (prev 28.88%; Δ 6.72% > 0%) |
| Interest Coverage Ratio: 2.53 > 6 (EBIT TTM 437.4m / Interest Expense TTM 172.8m) |
| A: 0.13 (Total Current Assets 3.94b - Total Current Liabilities 1.89b) / Total Assets 15.9b |
| B: 0.33 (Retained Earnings 5.23b / Total Assets 15.9b) |
| C: 0.03 (EBIT TTM 437.4m / Avg Total Assets 16.6b) |
| D: 1.90 (Book Value of Equity 10.3b / Total Liabilities 5.41b) |
| Altman-Z'' = 4.09 = AA |
| DSRI: 0.70 (Receivables 727.7m/879.7m, Revenue 5.91b/4.99b) |
| GMI: 0.32 (GM 7.72% / 23.89%) |
| AQI: 1.08 (AQ_t 0.22 / AQ_t-1 0.20) |
| SGI: 1.18 (Revenue 5.91b / 4.99b) |
| TATA: -0.10 (NI 224.2m - CFO 1.80b) / TA 15.9b) |
| Beneish M = -3.72 (Cap -4..+1) = AAA |
As of August 23, 2026, the stock is trading at USD 143.25 with a total of 3,220,128 shares traded. Over the past week, the price has changed by +5.21%, over one month by +20.76%, over three months by -15.47% and over the past year by +83.92%.
Current recommended Stop Loss: 136.00 (which is 5.1% or 1.4 ATR below the current price).
Albemarle has received a consensus analysts rating of 3.43. Therefore, it is recommended to hold ALB.
- StrongBuy: 6
- Buy: 3
- Hold: 17
- Sell: 1
- StrongSell: 1
| Analysts Target Price | 173.6 | 21.2% |
P/E Trailing = 497.0
P/E Forward = 18.018
P/S = 2.6803
P/B = 1.9708
P/EG = 0.7941
Revenue TTM = 5.91b USD
EBIT TTM = 437.4m USD
EBITDA TTM = 1.23b USD
Long Term Debt = 1.80b USD (from longTermDebt, last quarter)
Short Term Debt = 78.9m USD (from shortTermDebt, last quarter)
Debt = 2.09b USD (from shortLongTermDebtTotal, last quarter) + Leases 103.1m
Net Debt = 457.2m USD (calculated: Debt 2.09b - CCE 1.63b)
Enterprise Value = 16.3b USD (15.8b + Debt 2.09b - CCE 1.63b)
Interest Coverage Ratio = 2.53 (Ebit TTM 437.4m / Interest Expense TTM 172.8m)
EV/FCF = 12.14x (Enterprise Value 16.3b / FCF TTM 1.34b)
FCF Yield = 8.24% (FCF TTM 1.34b / Enterprise Value 16.3b)
FCF Margin = 22.72% (FCF TTM 1.34b / Revenue TTM 5.91b)
Net Margin = 3.79% (Net Income TTM 224.2m / Revenue TTM 5.91b)
Gross Margin = 23.89% ((Revenue TTM 5.91b - Cost of Revenue TTM 4.50b) / Revenue TTM)
Gross Margin QoQ = 33.86% (prev 35.06%)
Tobins Q-Ratio = 1.02 (Enterprise Value 16.3b / Total Assets 15.9b)
Interest Expense / Debt = 8.27% (Interest Expense 172.8m / Debt 2.09b)
Taxrate = 33.24% (90.7m / 272.9m)
NOPAT = 292.0m (EBIT 437.4m * (1 - 33.24%))
Current Ratio = 2.09 (Total Current Assets 3.94b / Total Current Liabilities 1.89b)
Debt / Equity = 0.20 (Debt 2.09b / totalStockholderEquity, last quarter 10.3b)
Debt / EBITDA = 0.37 (Net Debt 457.2m / EBITDA 1.23b)
Debt / FCF = 0.34 (Net Debt 457.2m / FCF TTM 1.34b)
Total Stockholder Equity = 9.91b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.35% (Net Income 224.2m / Total Assets 15.9b)
RoE = 2.26% (Net Income TTM 224.2m / Total Stockholder Equity 9.91b)
RoCE = 3.73% (EBIT 437.4m / Capital Employed (Equity 9.91b + L.T.Debt 1.80b))
RoIC = 2.12% (NOPAT 292.0m / Invested Capital 13.8b)
WACC = 12.12% (E(15.8b)/V(17.9b) * Re(12.99%) + D(2.09b)/V(17.9b) * Rd(8.27%) * (1-Tc(0.33)))
Discount Rate = 12.99% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 55.52 | Cagr: 6.81%
[DCF] Terminal Value 63.43% ; FCFF base≈1.34b ; Y1≈1.35b ; Y5≈1.43b
[DCF] Fair Price = 110.8 (EV 13.5b - Net Debt 457.2m = Equity 13.1b / Shares 118.0m; r=12.12% [WACC]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.46 | # QB: 0
Revenue Correlation: -82.80 | Revenue CAGR: -21.19% | SUE: 1.24 | # QB: 3
EPS current Quarter (2026-09-30): EPS=2.49 | Chg30d=-29.01% | Revisions=-10% | Analysts=13
EPS current Year (2026-12-31): EPS=11.54 | Chg30d=-7.88% | Revisions=-27% | GrowthEPS=+1560.3% | GrowthRev=+19.5%
EPS next Year (2027-12-31): EPS=11.50 | Chg30d=-9.20% | Revisions=-31% | GrowthEPS=-0.3% | GrowthRev=+3.1%
[Analyst] Revisions Ratio: -29% (up=11, down=21)